12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DPX-Survivac: Phase I started

Immunovaccine began the Phase I portion of a U.S. Phase I/II trial evaluating 3 doses of subcutaneous DPX-Survivac given 3 weeks apart. The open-label Phase I portion will evaluate 0.1 and 0.5 mL DPX-Survivac in combination with...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >